ClinicalTrials.gg

TargetBeta

PCSK9

proprotein convertase subtilisin/kexin type 9 · also NARC-1, FH3, HCHOLA3 · Proprotein convertase subtilisin/kexin family

11 programs in company-led studies act on PCSK9, from 10 companies: 5 in phase 3, 3 approved with new studies. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (10 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyFurthest phaseStudiesAlso acts onRead from
inclisiranruleNovartisphase 43715 running–the studies' text
evolocumabruleAmgenphase 4452 running–NCIt
alirocumabruleSanofiphase 4481 running–NCIt
lerodalcibepruleLIB Therapeuticsphase 3147 running–ChEMBL
QLC7401ruleQilu Pharmaceuticalphase 355 running–the studies' text
tafolecimabruleInnovent Biologicsphase 381 running–NCIt
recaticimabruleJiangsu HengRui Medicinephase 370 running–the studies' text
SAL003ruleShenzhen Salubris Pharmaceuticalsphase 330 running–the studies' text
VERVE-102Eli Lillyphase 222 running–a judged reading
DNV001ruleHangzhou Dinovate Biotechphase 211 running–the studies' text
RBD7022ruleQilu Pharmaceuticalphase 121 running–the studies' text

Conditions their studies are in

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.